RONICICLIB

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C18H21F3N4O3S
Molecular Weight	430.445
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@@H](O)[C@@H](C)OC1=C(C=NC(NC2=CC=C(C=C2)[S@](=N)(=O)C3CC3)=N1)C(F)(F)F

InChI

InChIKey=UELYDGOOJPRWGF-SRQXXRKNSA-N

InChI=1S/C18H21F3N4O3S/c1-10(26)11(2)28-16-15(18(19,20)21)9-23-17(25-16)24-12-3-5-13(6-4-12)29(22,27)14-7-8-14/h3-6,9-11,14,22,26H,7-8H2,1-2H3,(H,23,24,25)/t10-,11-,29+/m1/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/30677506 | https://www.ncbi.nlm.nih.gov/pubmed/30089585 | https://clinicaltrials.gov/ct2/show/NCT02047890 | https://clinicaltrials.gov/ct2/show/NCT01573338 | https://clinicaltrials.gov/ct2/show/NCT02161419

Roniciclib (BAY1000394) is a pan-cyclin-dependent kinase inhibitor that has been developed for treatment in small cell lung carcinoma and solid tumors. Roniciclib targets certain key proteins that are essential for the survival of cancer cells, resulting in decreased tumor growth. Phase I studies to evaluate the safety, tolerability and pharmacokinetics of roniciclib have been completed successfully. In phase II studies, roniciclib was found to be well tolerated and showed promising efficacy when combined with chemotherapy in small cell lung carcinoma patients. However, due to an observed safety signal (treatment-emergent adverse events) in one phase II study, other clinical trials have been discontinued and further development of roniciclib was terminated.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Cyclin-dependent kinase 1/cyclin B 5 Target ID: CHEMBL2094127 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22821149	Inhibitor 8504	7.0 nM [IC50]
Cyclin-dependent kinase 2/cyclin E 10 Target ID: CHEMBL2094126 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22821149	Inhibitor 8504	9.0 nM [IC50]
Cyclin-dependent kinase 4/cyclin D 2 Target ID: CHEMBL2095942 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22821149	Inhibitor 8504	11.0 nM [IC50]
CDK9/cyclin T1 4 Target ID: CHEMBL2111389 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22821149	Inhibitor 8504	5.0 nM [IC50]

PubMed

Title	Date	PubMed
The lab oddity prevails: discovery of pan-CDK inhibitor (R)-S-cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the treatment of cancer.	2013-07	23671017
BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application.	2012-10	22821149

Patents

Name

Type

Language

RONICICLIB

Official Name

English

roniciclib [INN]

Preferred Name

English

BAY1000394

Code

English

BAY10-00394

Code

English

BAY-1000394

Code

English

2-BUTANOL, 3-((2-((4-((S(R))-S-CYCLOPROPYLSULFONIMIDOYL)PHENYL)AMINO)-5-(TRIFLUOROMETHYL)-4-PYRIMIDINYL)OXY)-, (2R,3R)-

Common Name

English

(R)-S-CYCLOPROPYL-S-(4-((4-(((1R,2R)-2-HYDROXY-1-METHYLPROPYL)OXY)-5-(TRIFLUOROMETHYL)PYRIMIDIN-2-YL)AMINO)PHENYL)SULFOXIMIDE

Systematic Name

English

Roniciclib [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C2185